ReviewEuropean respiratory review : an official journal of the European Respiratory Society2022
Recent advances in the management of pulmonary hypertension with interstitial lung disease.
Review in European respiratory review : an official journal of the European Respiratory Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 53 citations in OpenAlex.
- Clinical Significance of Echocardiographic Parameters in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease.Journal of cardiovascular development and disease · 2026Article
- Pulmonary hypertension associated with interstitial lung disease: a state-of-the-art review.The European respiratory journal · 2026Review
- Emergency donor pericardial conduit for ruptured pulmonary artery in lung transplantation for severe PH: a case report.Journal of cardiothoracic surgery · 2026Article
- Real-World Outcomes of Inhaled Treprostinil in Pulmonary Hypertension Related to Interstitial Lung Disease: A Multicenter, Retrospective Analysis.Journal of cardiovascular development and disease · 2026Article
- Article
- Computed tomography imaging features of major pulmonary and extrapulmonary complications of fibrotic lung diseases.Einstein (Sao Paulo, Brazil) · 2026Review
- Latin American expert opinion paper on the diagnosis and treatment of pulmonary hypertension associated with interstitial lung disease.Frontiers in medicine · 2026Article
- Cachexia Phenotyping Through Morphofunctional Assessment and Mitocondrial Biomarkers (GDF-15 and PGC-1α) in Idiopathic Pulmonary Fibrosis.Nutrients · 2025Observational
- Integrating CT-Based Lung Fibrosis and MRI-Derived Right Ventricular Function for the Detection of Pulmonary Hypertension in Interstitial Lung Disease.Journal of clinical medicine · 2025Article
- Physician perspectives on pulmonary hypertension in ILD: results of a cases-based survey.BMC pulmonary medicine · 2025Article
- The global burden of heart failure attributable to interstitial lung diseases: insights from the global burden of disease study 2021.BMC cardiovascular disorders · 2025Article
- Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD): Back to the Future.Advances in therapy · 2025Review
- The Nutritional Phenotyping of Idiopathic Pulmonary Fibrosis Through Morphofunctional Assessment: A Bicentric Cross-Sectional Case-Control Study.Life (Basel, Switzerland) · 2025Article
- Review of the Diagnosis and Management of Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH).Journal of clinical medicine · 2025Review
- Right Heart Catheterization Accurately Diagnoses Pulmonary Hypertension in Patients With Interstitial Lung Disease: Results From a Long-Term Cohort Study.Pulmonary circulation · 2025Article
- Shining a spotlight on pulmonary hypertension associated with interstitial lung disease care: The latest advances in diagnosis and treatment.Journal of managed care & specialty pharmacy · 2025Review
- Endothelin receptor antagonists target EDNRB and modulate the progression of idiopathic pulmonary fibrosis via anoikis-related genes.Frontiers in medicine · 2025Article
- Outcomes and predictors of progression in progressive pulmonary fibrosis.Annals of medicine · 2024Article
- Development of a local nomogram-based scoring system for predicting overall survival in idiopathic pulmonary fibrosis: A rural appalachian experience.Medicine advances · 2024Article
- Converging Pathways: A Review of Pulmonary Hypertension in Interstitial Lung Disease.Life (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary hypertension (PH) is known to complicate various forms of interstitial lung disease (ILD), including idiopathic pulmonary fibrosis, the interstitial pneumonias and chronic hypersensitivity pneumonitis. Pathogenesis of PH-ILD remains incompletely understood, and probably has overlap with other forms of pre-capillary pulmonary hypertension. PH-ILD carries a poor prognosis, and is associated with increased oxygen requirements, and a decline in functional capacity and exercise tolerance. Despite most patients having mild-moderate pulmonary hypertension, more severe pulmonary hypertension and signs of right heart failure are observed in a subset of cases. Clinical suspicion and findings on pulmonary function, computed tomography and echocardiography are often the initial steps towards diagnosis. Definitive diagnosis is obtained by right heart catheterisation demonstrating pre-capillary pulmonary hypertension. Drugs approved for pulmonary arterial hypertension have been investigated in several randomised controlled trials in PH-ILD patients, leading to discouraging results until the recent INCREASE study. This review provides an overview of the current understanding, approach to diagnosis and recent advances in treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.